Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group
复制标题
DOI：
10.1016/j.leukres.2009.01.020
复制
发表时间：
2009-11-01
影响因子：
2.7
通讯作者：
Greipp, Philip R.
中科院分区：
文献类型：
--
作者：
Lacy, Martha Q.;Jacobus, Susanna;Greipp, Philip R.
东部肿瘤合作组 (ECOG) 进行了白细胞介素 12 (IL-12) 治疗平台期多发性骨髓瘤的 II 期试验。患者最初接受IL-12 250 ng/kg I.V.治疗。每 3 周每天一次，连续 5 天。在首批 16 名患者入组后，该试验因毒性而被修改。 IL-12 每周两次皮下注射 300 ng/kg，持续 24 周。在 48 名符合条件的患者中，有 4 名客观缓解 (8.3%)，均为 CR。中位生存期和无进展生存期分别为 42.8 个月和 11.4 个月。观察到不可接受的 3 级或 4 级非血液学毒性（皮下注射 IL-12 为 31%，静脉注射 IL-12 为 63%）。 (C) 2009 Elsevier Ltd. 保留所有权利。
The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300 ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed. (C) 2009 Elsevier Ltd. All rights reserved.